8-K 1 b39862tte8-k.txt TRANSKARYOTIC THERAPIES, INC. 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2001 ------------------ TRANSKARYOTIC THERAPIES, INC. -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in its Charter) Delaware ---------------- --------------------------------------------------------------- (State or Other Jurisdiction of Incorporation) 000-21481 04-3027191 --------------------------------- ------------------------------------- (Commission File Number) (IRS Employer Identification No.) 195 Albany Street, Cambridge, Massachusetts 02139 -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (617) 349-0200 -------------------------------------------------------------------------------- Registrant's Telephone Number, Including Area Code Not Applicable -------------------------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) 2 Item 5. OTHER EVENTS. On July 2, 2001, Transkaryotic Therapies, Inc. ("TKT") announced the completion of its follow-on public offering, raising a total of $100,177,500. A total of 3,515,000 shares were sold at $28.50 per share, including 415,000 shares to cover overallotments. SG Cowen Securities Corporation acted as underwriter for the common stock offering. -----------. The full text of TKT's press release issued in connection with the foregoing matter is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits. 99.1 Press Release -2- 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 2, 2001 REGISTRANT TRANSKARYOTIC THERAPIES, INC. By: /s/ Daniel E. Geffken ----------------------------------- Daniel E. Geffken Senior Vice President, Finance and Chief Financial Officer -3- 4 EXHIBIT INDEX EXHIBIT NUMBER DESCRIPTION -------------- ----------- 99.1 Press Release -4-